KPA will get tough on improper measures of some foreign-invested pharmaceutical firms

Published: 2002-10-31 06:58:00

Updated: 2002-10-31 06:58:00

"Proper countermeasures are contemplating to cope with improper and lukewarm attitudes of some foreign-invested pharmaceutical firms in their dealing with substandard products and failure in providing accurate drug information, after implementation of the system of separating drug dispensing from...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK